{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-152050","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.962171+00:00","generated_at":"2026-05-15T06:36:13.041245+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ALX Oncology appoints Jeff Knight as Chief Development and Operating Officer","bullets":["Jeff Knight, former CDOO at Crinetics, appointed effective April 13, 2026; role includes clinical development and operations.","Compensation: $565k base salary, 40% annual target bonus, and stock option for 800k shares under 2025 Inducement Plan.","Knight brings 30+ years experience; previously at Poseida, Halozyme, Amgen, and Genentech.","Company highlights upcoming catalysts for evorpacept and ALX2004 programs in next 12-18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-152050","json":"https://secwatch.observer/filing/0001193125-26-152050.json","markdown":"https://secwatch.observer/filing/0001193125-26-152050.md","text":"https://secwatch.observer/filing/0001193125-26-152050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/0001193125-26-152050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526152050/alxo-20260413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:36:13.041245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}